PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.205
https://www.valueinhealthjournal.com/article/S1098-3015(20)32461-X/fulltext
Section Title :
Section Order :
10154
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32461-X&doi=10.1016/j.jval.2020.08.205